The Cochlear (ASX:COH) share price tumbles 7% despite dividend boost

The implantable hearing device developer released it FY21 results this morning.

| More on:
Boxer falls down in the ring, indicating a share price performance low.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cochlear Ltd (ASX: COH) share price is tumbling in late morning trade, down 7.4% to $237.08 per share.

This comes despite the ASX healthcare company meeting guidance in its full year results for the 2021 financial year, released earlier today. And despite a boost to its dividend payout.

What dividend did Cochlear announce?

The Cochlear share price is falling even though the company boosted its full-year dividend by 59%, to $2.55.

Management was able to return some cash to investors' pockets after Cochlear saw sales revenue grow 10% in FY21, reaching $1.49 billion. Underlying net profit of $236.7 million was also up 54% year-on-year. And profits beat guidance, which management had forecast would come in the range of $225–245 million.

That, however, appears not to have satisfied many investors, with Cochlear dropping heavily even as the S&P/ASX 200 Index (ASX: XJO) edges up 0.3%.

So, why is the Cochlear share price tumbling?

My Foolish colleague James Mickleboro may have nailed the answer to that question before markets opened today, writing:

While Cochlear's profit was within its guidance range, it appears to have fallen short of the market's expectations. According to CommSec, the analyst consensus was a net profit after tax of $245.5 million. This could potentially weigh on the Cochlear share price today.

It's not uncommon for investors to punish stocks that fall short of consensus expectations.

Cochlear share price snapshot

Even with today's large drop, the Cochlear share price remains a standout performer in 2021, up 28% year-to-date. That's more than double the gains posted by the ASX 200 this calendar year.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

The next 3 years could be huge for this ASX healthcare stock. Here's why

Today's update has put this ASX healthcare stock back in the spotlight as investors reassess its long-term growth potential.

Read more »

A doctor sits with a patient and uses a pen to point to certain parts of her mammogram scan
Healthcare Shares

Top broker says this ASX small-cap healthcare stock could be set to double

This company is making significant clinical and commercial progress .

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

3 quality ASX healthcare shares worth buying now

Brokers think the tide is turning for these battling medical heavyweights.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Early success in battling Crohn's Disease has sent this ASX biotech's shares soaring

The early-stage results have been described as outstanding.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

Why are 4DMedical shares in a trading halt today?

The company is looking to raise fresh capital.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

This ASX biotech's shares are up strongly on good news out of the US

The addressable market for this newly approved software is huge.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

Which biotech company's shares have rocketed to a new high on good news?

A key US approval is great news for this company.

Read more »

Health professional working on his laptop.
Healthcare Shares

Insiders are buying. Can Pro Medicus shares finally turn the corner?

Insider buying puts Pro Medicus shares in focus after steep pullback, raising questions about downside risk and upside potential.

Read more »